Literature DB >> 11898565

Herpes zoster infection and postherpetic neuralgia.

R B Tenser1.   

Abstract

Varicella-zoster virus (VZV), the cause of chicken pox, establishes latent infection in sensory ganglia. Reactivation results in zoster (shingles), sometimes complicated by encephalitis (myelitis). Postherpetic neuralgia (PHN) is the major morbidity of zoster. PHN typically increases in frequency with age. The VZV vaccine, which was developed for children, may be effective in enhancing VZV immune reactivity and decreasing zoster in adults. Early antiviral treatment may be effective in decreasing PHN onset. Several other medications may be useful in treating established PHN. A recent report discussed intrathecal steroid use.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898565     DOI: 10.1007/s11910-001-0057-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   6.030


  46 in total

1.  A new treatment for postherpetic neuralgia.

Authors:  C P Watson
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

2.  Persistence of varicella-zoster virus DNA in elderly patients with postherpetic neuralgia.

Authors:  R Mahalingam; M Wellish; J Brucklier; D H Gilden
Journal:  J Neurovirol       Date:  1995-03       Impact factor: 2.643

3.  Somatosensory findings in postherpetic neuralgia.

Authors:  T Nurmikko; D Bowsher
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

4.  Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA.

Authors:  R J Cohrs; M Barbour; D H Gilden
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Expression of protein encoded by varicella-zoster virus open reading frame 63 in latently infected human ganglionic neurons.

Authors:  R Mahalingam; M Wellish; R Cohrs; S Debrus; J Piette; B Rentier; D H Gilden
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

6.  Patterns of gene expression and sites of latency in human nerve ganglia are different for varicella-zoster and herpes simplex viruses.

Authors:  K D Croen; J M Ostrove; L J Dragovic; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 7.  Recent advances in varicella-zoster virus infection.

Authors:  J I Cohen; P A Brunell; S E Straus; P R Krause
Journal:  Ann Intern Med       Date:  1999-06-01       Impact factor: 25.391

8.  Zoster myelitis: improvement with antiviral therapy in two cases.

Authors:  S M de Silva; A S Mark; D H Gilden; R Mahalingam; M Balish; F Sandbrink; S Houff
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

9.  CSF and MRI findings in patients with acute herpes zoster.

Authors:  M Haanpää; P Dastidar; A Weinberg; M Levin; A Miettinen; A Lapinlampi; P Laippala; T Nurmikko
Journal:  Neurology       Date:  1998-11       Impact factor: 9.910

10.  Varicella-zoster virus transcription in human trigeminal ganglia.

Authors:  J L Meier; R P Holman; K D Croen; J E Smialek; S E Straus
Journal:  Virology       Date:  1993-03       Impact factor: 3.616

View more
  2 in total

1.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

2.  A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax.

Authors:  Larry I Gilderman; James F Lawless; Thomas M Nolen; Tina Sterling; Ruth Z Rutledge; Doreen A Fernsler; Neal Azrolan; Santosh C Sutradhar; William W Wang; Ivan S F Chan; Katia Schlienger; Florian Schödel; Jeffrey L Silber
Journal:  Clin Vaccine Immunol       Date:  2007-12-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.